MORPHINE SULFATE INJECTION USP SOLUTION

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

MORPHINE SULFATE

Saadav alates:

PFIZER CANADA ULC

ATC kood:

N02AA01

INN (Rahvusvaheline Nimetus):

MORPHINE

Annus:

2MG

Ravimvorm:

SOLUTION

Koostis:

MORPHINE SULFATE 2MG

Manustamisviis:

INTRAMUSCULAR

Ühikuid pakis:

10X1 ML

Retsepti tüüp:

Narcotic (CDSA I)

Terapeutiline ala:

OPIATE AGONISTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0104545008; AHFS:

Volitamisolek:

CANCELLED PRE MARKET

Loa andmise kuupäev:

2019-03-04

Toote omadused

_ _
_Product Monograph - _
_N_
_MORPHINE SULFATE INJECTION USP _
_Page 1 of 33 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
N
MORPHINE SULFATE INJECTION USP
Sterile Solution
2 mg/mL, 10 mg/mL and 15 mg/mL
Narcotic Analgesic
Pfizer Canada Inc
17300 Trans-Canada Highway
Kirkland, Québec
H9J 2M5
Date of Revision:
October 3, 2018
Submission Control No: 219782
_ _
_Product Monograph - _
_N_
_MORPHINE SULFATE INJECTION USP _
_Page 2 of 33 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................13
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................15
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND STABILITY
..........................................................................................22
SPECIAL HANDLING INSTRUCTIONS
.......................................................................22
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................22
PART II: SCIENTIFIC INFORMATION
................................................................................24
PHARMACEUTICAL INFORMATION
...................